, Volume 20, Issue 1, pp 23–36 | Cite as


Health-Related Quality of Life Considerations
  • James W. Shaw
  • Vijay N. Joish
  • Stephen Joel Coons
Review Article


The symptoms of onychomycosis and their impact on personal appearance are important determinants of patients’ perceptions of their own health. The effect of onychomycosis is greater on psychosocial than physical functioning and is directly related to the extent of nail involvement.

This review identified a number of disease-targeted questionnaires that have been developed to assess the impact of onychomycosis and its treatment on health-related quality of life (HR-QOL). The instruments differ considerably in the extent to which they have been psychometrically tested. Most have been shown to provide both valid and reliable measurement of HR-QOL in patients with onychomycosis of the toes. However, not all have been tested in patients with fingernail disease. The generic and disease-targeted scales of most of the available questionnaires exhibit poor variability, which may limit their responsiveness to clinically important change.

Only one instrument, the Onychomycosis Disease-Specific Questionnaire, has been incorporated into a clinical trial. Thus, information relating to the impact of onychomycosis treatment on HR-QOL is limited. Future efforts should focus on the systematic evaluation of existing questionnaires in all populations for which they were developed. In addition, it is important that disease-targeted measures be included in future clinical trials so that a better understanding of the impact of onychomycosis treatment on patient HR-QOL may be gained.


Generic Scale Terbinafine General Health Perception Physical Functioning Scale Health Distress 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors did not receive any payment for the preparation of this manuscript.


  1. 1.
    Midgley G, Moore MK, Cook JC, et al. Mycology of nail disorders. J Am Acad Dermatol 1994; 31 (3 Pt 2): S68–74PubMedCrossRefGoogle Scholar
  2. 2.
    Arikian SR, Einarson TR, Kobelt-Nguyen G, et al. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br J Dermatol 1994; 130 Suppl. 43: 35–44PubMedCrossRefGoogle Scholar
  3. 3.
    Einarson TR, Gupta AK, Shear NH, et al. Clinical and economic factors in the treatment of onychomycosis. Pharmacoeconomics 1996; 9 (4): 307–20PubMedCrossRefGoogle Scholar
  4. 4.
    Marchetti A, Piech CT, McGhan WF, et al. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther 1996; 18 (4): 757–77PubMedCrossRefGoogle Scholar
  5. 5.
    Scher RK. Onychomycosis is more than a cosmetic problem. Br J Dermatol 1994; 130 Suppl. 43: 15PubMedCrossRefGoogle Scholar
  6. 6.
    Lubeck DP, Patrick DL, McNulty P, et al. Quality of life persons with onychomycosis. Qual Life Res 1993; 341–8Google Scholar
  7. 7.
    Lubeck DP. Measuring health-related quality of life in onychomycosis. J Am Acad Dermatol 1998; 38 (5 Pt 3): S64–8PubMedCrossRefGoogle Scholar
  8. 8.
    Drake LA, Patrick DL, Fleckman P, et al. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol 1999; 41 (2 Pt 1): 189–96PubMedCrossRefGoogle Scholar
  9. 9.
    Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998; 38 (5 Pt 1): 702–4PubMedCrossRefGoogle Scholar
  10. 10.
    Drake L. Quality of life issues for patients with fungal nail infections. AIDS Patient Care 1995; 9 Suppl 1: S15–7PubMedGoogle Scholar
  11. 11.
    Hong JJ, Stiller MJ, Menn E, et al. A pilot study to determine the biopsychosocial effects of onychomycosis on a northeastern American subpopulation [abstract]. J Invest Dermatol 1995; 104: 668Google Scholar
  12. 12.
    Whittam LR, Hay RJ. The impact of onychomycosis on quality of life. Clin Exp Dermatol 1997; 22 (2): 87–9PubMedCrossRefGoogle Scholar
  13. 13.
    Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 1997; 36 (10): 754–6PubMedCrossRefGoogle Scholar
  14. 14.
    Haneke E. Achilles Foot-Screening Project: background, objectives and design (discussion S17). J Eur Acad Dermatol Venereol 1999; 12 Suppl. 1: S2–5PubMedGoogle Scholar
  15. 15.
    Roseeuw D. Achilles Foot-Screening Project: preliminary results of patients screened by dermatologists (discussion S17). J Eur Acad Dermatol Venereol 1999; 12 Suppl. 1: S6–9PubMedGoogle Scholar
  16. 16.
    Opp K. Patients’ feelings and attitudes about their nail conditions. AIDS Patient Care 1995; 9 Suppl. 1: S18PubMedGoogle Scholar
  17. 17.
    Schein JR, Gause D, Stier DM, et al. Onychomycosis: baseline results of an observational study. J Am Podiatr Med Assoc 1997; 87 (11): 512–9PubMedGoogle Scholar
  18. 18.
    Lubeck DP, Gause D, Schein JR, et al. A health-related quality of life measure for use in patients with onychomycosis: a validation study. Qual Life Res 1999; 8 (1–2): 121–9PubMedCrossRefGoogle Scholar
  19. 19.
    Lubeck DP, Schein JR, Gause D, et al. Health-related quality of life in patients with toenail onychomycosis: data from a 9-month observational study. JCOM 1999; 6 (8): 37–42Google Scholar
  20. 20.
    Turner RR, Testa MA. Measuring the impact of onychomycosis on patient quality of life. Qual Life Res 2000; 9 (1): 39–53PubMedCrossRefGoogle Scholar
  21. 21.
    Pollak R, Billstein SA. Efficacy of terbinafine for toenail onychomycosis: a multicenter trial of various treatment durations. J Am Podiatr Med Assoc 2001; 91 (3): 127–31PubMedGoogle Scholar
  22. 22.
    Millikan LE, Powell DW, Drake LA. Quality of life for patients with onychomycosis. Int J Dermatol 1999; 38 Suppl. 2: 13–6PubMedCrossRefGoogle Scholar
  23. 23.
    Mathes EW, Kahn A. Physical attractiveness, happiness, neuroticism, and self-esteem. J Psychol 1975; 90 (1st half): 27–30PubMedGoogle Scholar
  24. 24.
    Scher RK. Onychomycosis: a significant medical disorder. J Am Acad Dermatol 1996; 35 (3 Pt 2): S2–5PubMedCrossRefGoogle Scholar
  25. 25.
    Coons SJ, Rao S, Keininger DL, et al. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000; 17 (1): 13–35PubMedCrossRefGoogle Scholar
  26. 26.
    Lohr KN, Aaronson NK, Alonso J, et al. Evaluating quality of life and health status instruments: development of scientific review criteria. Clin Ther 1996; 18 (5): 979–92PubMedCrossRefGoogle Scholar
  27. 27.
    Testa MA. Quality-of-life assessment in diabetes research: interpreting the magnitude and meaning of treatment effects. Diabetes Spectrum 2000; 13 (1): 29–35Google Scholar
  28. 28.
    Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297–334CrossRefGoogle Scholar
  29. 29.
    Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York (NY): McGraw-Hill, 1994Google Scholar
  30. 30.
    Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979; 86 (2): 420–8PubMedCrossRefGoogle Scholar
  31. 31.
    Cook TD, Campbell DT. Quasi-experimentation: design and analysis issues for field settings. Boston (MA): Houghton Mifflin, 1979Google Scholar
  32. 32.
    Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. New York (NY): Oxford Medical Publications, 1996Google Scholar
  33. 33.
    Stewart AL, Ware JE, editors. Measuring functioning and well-being: theMedical Outcomes Study approach. Durham (NC): Duke University Press, 1992Google Scholar
  34. 34.
    Fleming JS, Courtney BE. The dimensionality of self-esteem. II: hierarchical facet models for revised measurement scales. J Pers Soc Psychol 1984; 46: 404–21CrossRefGoogle Scholar
  35. 35.
    Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey manual and interpretation guide. Boston (MA): The Health Institute, 1993Google Scholar
  36. 36.
    Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34 (3): 220–33PubMedCrossRefGoogle Scholar
  37. 37.
    Dupuy HJ. The psychological general well-being (PGWB) index. In: Wenger NK, Mattson ME, Furberg CD, et al., editors. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq Publishing, 1984: 170–83Google Scholar
  38. 38.
    Nieworth M, Korting HC. Management of onychomycosis. Drugs 1999; 58 (2): 283–96CrossRefGoogle Scholar
  39. 39.
    Roberts DT. Onychomycosis: current treatment and future challenges. Br J Dermatol 1999; 141 Suppl. 56: 1–4PubMedCrossRefGoogle Scholar
  40. 40.
    Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27 Suppl. 3: S217–32PubMedCrossRefGoogle Scholar
  41. 41.
    Deyo RA, Patrick DL. Barriers to the use of health status measures in clinical investigation, patient care, and policy research. Med Care 1989; 27 Suppl. 3: S254–68PubMedCrossRefGoogle Scholar
  42. 42.
    Murawski MM, Miederhoff PA. On the generalizability of statistical expressions of health related quality of life instrument responsiveness: a data synthesis. Qual Life Res 1998; 7 (1): 11–22PubMedCrossRefGoogle Scholar
  43. 43.
    Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993; 118 (8): 622–9PubMedGoogle Scholar
  44. 44.
    Epstein RS. Responsiveness in quality-of-life assessment: nomenclature, determinants, and clinical applications. Med Care 2000; 38 Suppl. II: II91–4PubMedGoogle Scholar
  45. 45.
    Bombardier C, Ware J, Russell IJ, et al. Auranofin therapy and quality of life in patients with rheumatoid arthritis: results of a multicenter trial. Am J Med 1986; 81 (4): 565–75PubMedCrossRefGoogle Scholar
  46. 46.
    Temkin NR, Dikmen S, Machamer J, et al. General versus disease-specific measures: further work on the Sickness Impact Profile for head injury. Med Care 1989; 27 Suppl. 3: S44–53PubMedCrossRefGoogle Scholar
  47. 47.
    Kennedy P. A guide to econometrics. 4th ed. Cambridge (MA): MIT Press, 1998Google Scholar
  48. 48.
    Burke LB. US regulation of pharmaceutical outcomes research. Value Health 2001; 4 (1): 5–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • James W. Shaw
    • 1
  • Vijay N. Joish
    • 1
  • Stephen Joel Coons
  1. 1.Department of Pharmaceutical Sciences and the Center for Health Outcomes and PharmacoEconomic Research, College of PharmacyUniversity of ArizonaTucsonUSA

Personalised recommendations